Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness

University of Toronto

$100,000.00

Real-world Effects of Bisphosphonates: Using Innovation to Link Datasets (REBUILD) - Phase I

EF 2009-10

Résumé
Osteoporosis is a major public health issue resulting in considerable fracture-related morbidity. In Canada, oral bisphosphonates are the primary drugs used to treat osteoporosis and prevent fractures. Based on results from placebo-controlled trials, Canadian osteoporosis practice guidelines recommend alendronate and risedronate as first-choice options, and etidronate as a second-choice option. In contrast, many public drug plans across Canada limit access to alendronate and risedronate, yet provide unrestricted coverage for etidronate--the least expensive treatment. Nonetheless, little information is available that directly compares the effectiveness of oral bisphosphonates in reducing fracture risk. We will bridge this knowledge gap by examining the comparative effectiveness of oral bisphosphonates in reducing fracture risk by studying new users of these agents in British Columbia and Ontario. Results will be important to guide drug policy and treatment decision-making, and ultimately help to reduce the burden of fracture-related morbidity in Canada.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
192709
Name
Cadarette Suzanne M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Real-world Effects of Bisphosphonates: Using Innovation to Link Datasets (REBUILD) - Phase I
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Analytic Methods; Bisphosphonates; Effectiveness; Fracture; Osteoporosis; Pharmacoepidemiology
Abstract
Osteoporosis is a major public health issue resulting in considerable fracture-related morbidity. In Canada, oral bisphosphonates are the primary drugs used to treat osteoporosis and prevent fractures. Based on results from placebo-controlled trials, Canadian osteoporosis practice guidelines recommend alendronate and risedronate as first-choice options, and etidronate as a second-choice option. In contrast, many public drug plans across Canada limit access to alendronate and risedronate, yet provide unrestricted coverage for etidronate--the least expensive treatment. Nonetheless, little information is available that directly compares the effectiveness of oral bisphosphonates in reducing fracture risk. We will bridge this knowledge gap by examining the comparative effectiveness of oral bisphosphonates in reducing fracture risk by studying new users of these agents in British Columbia and Ontario. Results will be important to guide drug policy and treatment decision-making, and ultimately help to reduce the burden of fracture-related morbidity in Canada.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cadarette, Suzanne M
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $20,000~ $0~~ $80,000~ $0~